CoChat

Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues

Open access
Manfredsson, Fredric P., Bloom, David C., Mandel, Ronald J. · 2012 · Neurobiology of Disease
Cited by 29

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The field of in vivo gene therapy has matured to the point where there are numerous clinical trials underway including late-stage clinical trials. Several viral vectors are especially efficient and support lifetime protein expression in the brain and a number of clinical trials are underway for various progressive or chronic neurological disorders including Parkinson's disease, Alzheimer's disease, and Batten's disease. To date, however, none of the vectors in clinical use have any direct way to reverse or control their transgene product in the event continued protein expression should become problematic. Several schemes that use elements within the vector design have been developed that allow an external drug or pro-drug to alter ongoing protein expression after in vivo gene transfer. The most promising and most studied regulated protein expression methods for in vivo gene transfer are reviewed. In addition, potential scientific and clinical advantages of transgene regulation for gene therapy are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2012.03.001

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 76

  1. Auslander, 2010, A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression, Mol. Biosyst., 6, 807, 10.1039/b923076a · DOI
  2. Banaszynski, 2008, Chemical control of protein stability and function in living mice, Nat. Med., 14, 1123, 10.1038/nm.1754 · DOI · Paper page
  3. Barza, 1975, Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs, Antimicrob. Agents Chemother., 8, 713, 10.1128/AAC.8.6.713 · DOI · Paper page
  4. Bass, 2010, Optogenetic control of striatal dopamine release in rats, J. Neurochem., 114, 1344, 10.1111/j.1471-4159.2010.06850.x · DOI · Paper page
  5. Benzekhroufa, 2009, Targeting central serotonergic neurons with lentiviral vectors based on a transcriptional amplification strategy, Gene Ther., 16, 681, 10.1038/gt.2009.7 · DOI
  6. Berman, 2007, Update on rosacea and anti-inflammatory-dose doxycycline, Drugs Today (Barc.), 43, 27, 10.1358/dot.2007.43.1.1025697 · DOI
  7. Blasey, 2011, Efficacy and safety of mifepristone for the treatment of psychotic depression, J. Clin. Psychopharmacol., 31, 436, 10.1097/JCP.0b013e3182239191 · DOI · Paper page
  8. Burcin, 1999, Adenovirus-mediated regulable target gene expression in vivo, Proc. Natl. Acad. Sci. U. S. A., 96, 355, 10.1073/pnas.96.2.355 · DOI · Paper page
  9. Cao, 2009, Molecular therapy of obesity and diabetes by a physiological autoregulatory approach, Nat. Med., 15, 447, 10.1038/nm.1933 · DOI · Paper page
  10. Caron, 2005, The Lac repressor provides a reversible gene expression system in undifferentiated and differentiated embryonic stem cell, Cell. Mol. Life Sci., 62, 1605, 10.1007/s00018-005-5123-2 · DOI
  11. Chang, 2008, Molecular, cellular, and behavioral characterization of a tetracycline (Tet)-regulated rAAV vector for human aromatic amino acid decarboxylase (hAADC) in a rat model of Parkinson's disease (PD), Mol. Ther., 16, S264, 10.1016/S1525-0016(16)40109-7 · doi:10.1016/s1525-0016(16)40109-7
  12. Chojnacki, 2009, Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both?, Nat. Rev. Neurosci., 10, 153, 10.1038/nrn2571 · DOI · Paper page
  13. Christopherson, 1992, Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators, Proc. Natl. Acad. Sci. U. S. A., 89, 6314, 10.1073/pnas.89.14.6314 · DOI · Paper page
  14. Chtarto, 2003, Tetracycline-inducible transgene expression mediated by a single AAV vector, Gene Ther., 10, 84, 10.1038/sj.gt.3301838 · DOI · Paper page
  15. Chtarto, 2007, Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector, Exp. Neurol., 204, 387, 10.1016/j.expneurol.2006.11.014 · DOI
  16. Cronin, 2001, The lac operator–repressor system is functional in the mouse, Genes Dev., 15, 1506, 10.1101/gad.892001 · DOI · Paper page
  17. Culler, 2010, Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins, Science, 330, 1251, 10.1126/science.1192128 · DOI · Paper page
  18. Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 · DOI · Paper page
  19. Fiala, 2010, Optogenetic approaches in neuroscience, Curr. Biol., 20, R897, 10.1016/j.cub.2010.08.053 · DOI
  20. Forsayeth, 2011, AAV9: over the fence and into the woods, Mol. Ther., 19, 1006, 10.1038/mt.2011.95 · DOI · Paper page
  21. Georgievska, 2004, Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector, Hum. Gene Ther., 15, 934, 10.1089/hum.2004.15.934 · DOI · Paper page
  22. Golde, 2011, Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift, Neuron, 69, 203, 10.1016/j.neuron.2011.01.002 · DOI · Paper page
  23. Gordon, 1996, Detection of herpes simplex virus (types 1 and 2) and human herpesvirus 6 DNA in human brain tissue by polymerase chain reaction, Clin. Diagn. Virol., 6, 33, 10.1016/0928-0197(95)00203-0 · DOI
  24. Gross, 2009, Mifepristone treatment of olanzapine-induced weight gain in healthy men, Adv. Ther., 26, 959, 10.1007/s12325-009-0070-1 · DOI
  25. Haberman, 2002, Regulation of gene expression in adeno-associated virus vectors in the brain, Methods, 28, 219, 10.1016/S1046-2023(02)00226-8 · DOI
  26. Hadaczek, 2011, Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system, PLoS One, 6, e27728, 10.1371/journal.pone.0027728 · DOI · Paper page
  27. Ho, 1996, Dimeric ligands define a role for transcriptional activation domains in reinitiation, Nature, 382, 822, 10.1038/382822a0 · DOI · Paper page
  28. Hou, 2007, A novel adenoviral vector-mediated neuronal selective gene expression in neonatal mouse brain in response to hypoxia, Neurosci. Lett., 419, 23, 10.1016/j.neulet.2007.03.059 · doi:10.1016/j.neulet.2007.03.059
  29. Hu, 1987, The inducible lac operator–repressor system is functional in mammalian cells, Cell, 48, 555, 10.1016/0092-8674(87)90234-0 · DOI · Paper page
  30. Hurttila, 2008, Oxidative stress-inducible lentiviral vectors for gene therapy, Gene Ther., 15, 1271, 10.1038/gt.2008.75 · DOI
  31. Hwang, 2001, A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons, Hum. Gene Ther., 12, 1731, 10.1089/104303401750476230 · DOI · Paper page
  32. Iwamoto, 2010, A general chemical method to regulate protein stability in the mammalian central nervous system, Chem. Biol., 17, 981, 10.1016/j.chembiol.2010.07.009 · DOI · Paper page
  33. Jakobsson, 2003, Targeted transgene expression in rat brain using lentiviral vectors, J. Neurosci. Res., 73, 876, 10.1002/jnr.10719 · DOI · Paper page
  34. Jakobsson, 2004, Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector, Eur. J. Neurosci., 19, 761, 10.1111/j.0953-816X.2003.03147.x · DOI · Paper page
  35. Karatas, 2008, Investigation of HSV-1, HSV-2, CMV, HHV-6 and HHV-8 DNA by real-time PCR in surgical resection materials of epilepsy patients with mesial temporal lobe sclerosis, J. Neurol. Sci., 264, 151, 10.1016/j.jns.2007.08.010 · DOI
  36. Lamartina, 2003, Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates, Mol. Ther., 7, 271, 10.1016/S1525-0016(02)00051-5 · DOI · Paper page
  37. Lewin, 2001, Ribozyme gene therapy: applications for molecular medicine, Trends Mol. Med., 7, 221, 10.1016/S1471-4914(01)01965-7 · DOI
  38. Liu, 1997, Identification of cell type-specific promoter elements associated with the rat tyrosine hydroxylase gene using transgenic founder analysis, Brain Res. Mol. Brain Res., 50, 33, 10.1016/S0169-328X(97)00163-0 · DOI
  39. Liu, 2008, Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea, Mol. Ther., 16, 474, 10.1038/sj.mt.6300379 · DOI
  40. Lonergan, 2005, Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression, Physiol. Genomics, 20, 165, 10.1152/physiolgenomics.00120.2004 · DOI
  41. Lowenstein, 2007, Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions, Curr. Gene Ther., 7, 347, 10.2174/156652307782151498 · DOI · Paper page
  42. Mandel, 2006, Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders, Mol. Ther., 13, 463, 10.1016/j.ymthe.2005.11.009 · DOI · Paper page
  43. Manfredsson, 2009, Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector, Mol. Ther., 17, 1857, 10.1038/mt.2009.196 · DOI · Paper page
  44. Manfredsson, 2009, Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease, Curr. Gene Ther., 9, 375, 10.2174/156652309789753400 · DOI
  45. Manfredsson, 2009, Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity, Mol. Ther., 17, 980, 10.1038/mt.2009.45 · DOI · Paper page
  46. Mansuy, 2000, Tetracycline-regulated gene expression in the brain, Curr. Opin. Neurobiol., 10, 593, 10.1016/S0959-4388(00)00127-6 · DOI
  47. Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol., 9, 1164, 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
  48. Min, 1994, 5′ Upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice, Brain Res. Mol. Brain Res., 27, 281, 10.1016/0169-328X(94)90011-6 · DOI
  49. No, 1996, Ecdysone-inducible gene expression in mammalian cells and transgenic mice, Proc. Natl. Acad. Sci. U. S. A., 93, 3346, 10.1073/pnas.93.8.3346 · DOI · Paper page
  50. Nordstrom, 2003, The antiprogestin-dependent GeneSwitch system for regulated gene therapy, Steroids, 68, 1085, 10.1016/j.steroids.2003.07.008 · DOI
  51. Oh, 2009, Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter, Gene Ther., 16, 437, 10.1038/gt.2008.148 · DOI · Paper page
  52. Oligino, 1998, Drug inducible transgene expression in brain using a herpes simplex virus vector, Gene Ther., 5, 491, 10.1038/sj.gt.3300612 · DOI
  53. Peel, 1997, Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters, Gene Ther., 4, 16, 10.1038/sj.gt.3300358 · DOI · Paper page
  54. Pollock, 2000, Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector, Proc. Natl. Acad. Sci. U. S. A., 97, 13221, 10.1073/pnas.230446297 · DOI
  55. Rivera, 1996, A humanized system for pharmacologic control of gene expression, Nat. Med., 2, 1028, 10.1038/nm0996-1028 · DOI · Paper page
  56. Rivera, 2000, Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum, Science, 287, 826, 10.1126/science.287.5454.826 · DOI · Paper page
  57. Rock, 1983, Detection of HSV-1 genome in central nervous system of latently infected mice, Nature, 302, 523, 10.1038/302523a0 · DOI · Paper page
  58. Shen, 2006, Adeno-associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice, Stroke, 37, 2601, 10.1161/01.STR.0000240407.14765.e8 · DOI · Paper page
  59. Suess, 2003, Conditional gene expression by controlling translation with tetracycline-binding aptamers, Nucleic Acids Res., 31, 1853, 10.1093/nar/gkg285 · DOI
  60. Svedhem, 1979, Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment, J. Antimicrob. Chemother., 5, 717, 10.1093/jac/5.6.717 · doi:10.1093/jac/5.6.717
  61. Szulc, 2008, Conditional gene expression and knockdown using lentivirus vectors encoding shRNA, Methods Mol. Biol., 434, 291
  62. Szymanski, 2006, Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells, J. Gene Med., 8, 514, 10.1002/jgm.875 · doi:10.1002/jgm.875
  63. Szymanski, 2007, Development and validation of a robust and versatile one-plasmid regulated gene expression system, Mol. Ther., 15, 1340, 10.1038/sj.mt.6300171 · DOI
  64. Tang, 2002, Vigilant vectors: adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases, Methods, 28, 259, 10.1016/S1046-2023(02)00231-1 · DOI
  65. Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121 · DOI · Paper page
  66. Vaillancourt, 2003, Retroviral delivery of the ecdysone-regulatable gene expression system, Biotechnol. Prog., 19, 1750, 10.1021/bp0341085 · doi:10.1021/bp0341085
  67. Wang, 1994, A regulatory system for use in gene transfer, Proc. Natl. Acad. Sci. U. S. A., 91, 8180, 10.1073/pnas.91.17.8180 · DOI · Paper page
  68. Warren, 1977, Isolation of Herpes simplex virus from human trigeminal ganglia, including ganglia from one patient with multiple sclerosis, Lancet, 2, 637, 10.1016/S0140-6736(77)92501-6 · doi:10.1016/s0140-6736(77)92501-6
  69. Williams, 2001, Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas, Mol. Ther., 4, 593, 10.1006/mthe.2001.0499 · DOI
  70. Xie, 2008, A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types, Toxicol. In Vitro, 22, 261, 10.1016/j.tiv.2007.08.019 · DOI
  71. Xie, 2011, MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression, Mol. Ther., 19, 526, 10.1038/mt.2010.279 · DOI · Paper page
  72. Xiong, 2008, Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain, Mol. Ther., 16, 343, 10.1038/sj.mt.6300375 · DOI
  73. Xu, 2006, Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States, JAMA, 296, 964, 10.1001/jama.296.8.964 · DOI · Paper page
  74. Yang, 2009, Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model, J. Gene Med., 11, 899, 10.1002/jgm.1377 · DOI
  75. Ye, 1999, Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer, Science, 283, 88, 10.1126/science.283.5398.88 · DOI · Paper page
  76. Yen, 2004, Exogenous control of mammalian gene expression through modulation of RNA self-cleavage, Nature, 431, 471, 10.1038/nature02844 · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Manfredsson, F. P., Bloom, D. C., & Mandel, R. J.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2012-11
Volume
48
Issue
2
Pages
212-221
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2042759985
Cited by
29
References
14
FWCI
2.83
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues. https://app.cochat.ai/papers/10.1016/j.nbd.2012.03.001
The paper
Manfredsson, F. P., Bloom, D. C., & Mandel, R. J. (2012). Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2012.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.